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Chronic wasting disease (CWD) is a contagious, fatal 
prion disease of deer and elk that continues to emerge in 
new locations. To explore the means by which prions are 
transmitted with high efficiency among cervids, we examined 
prion infectivity in the apical skin layer covering the growing 
antler (antler velvet) by using CWD-susceptible transgenic 
mice and protein misfolding cyclic amplification. Our finding 
of prions in antler velvet of CWD-affected elk suggests that 
this tissue may play a role in disease transmission among 
cervids. Humans who consume antler velvet as a nutritional 
supplement are at risk for exposure to prions. The fact that 
CWD prion incubation times in transgenic mice expressing 
elk prion protein are consistently more rapid raises the pos-
sibility that residue 226, the sole primary structural differ-
ence between deer and elk prion protein, may be a major 
determinant of CWD pathogenesis.
C
hronic  wasting  disease  (CWD)  of  deer,  elk,  and 
moose is the only recognized prion disease of wild 
animals. To date, 15 US states and 2 Canada provinces 
have reported CWD in wild and/or farm-raised cervids. 
Outbreaks have also occurred in South Korea as a result 
of importation of subclinically infected animals (1,2). The 
unparalleled efficiency of prion transmission in cervids by 
a largely undefined mechanism, combined with high deer 
densities in certain areas of North America, complicates 
strategies for controlling CWD as it continues to emerge 
in new locations.
Growing antlers of male cervids are covered by a high-
ly innervated and vascularized apical skin layer, referred 
to as velvet, which is shed after an increase in testoster-
one and ossification of antlers. Our study objective was 
to assess whether velvet from CWD-infected elk contains 
prion infectivity. Our rationale was 2-fold. First, the an-
nual shedding of this material raises the possibility that it 
may play a role in CWD transmission. Second, although 
the most likely means of human exposure to CWD prions 
is consumption of contaminated venison (3), the substantial 
market for velvet in traditional Asian medicine also war-
rants concern.
We used CWD-susceptible transgenic (Tg) mice as a 
sensitive means to detect prions in antler velvet. Bioassays 
in Tg mice expressing deer prion protein (PrP) (4) and new-
ly created Tg mice expressing elk PrP, demonstrated low 
levels of CWD prions in antler velvet. We also show that 
the associated protease-resistant PrP could be amplified in 
vitro (for detection by Western blot) by protein misfolding 
cyclic amplification (PMCA). Finally, comparative CWD 
transmissions in Tg mice indicated that the glutamine (Q) 
to glutamic acid (E) variation at residue 226, which is the 
sole  primary  structural  difference  between  deer  and  elk 
PrP, may be a major determinant of CWD pathogenesis in 
these 2 species.
Materials and Methods
Production of Transgenic Mice
Tg(CerPrP)1536+/–   mice  expressing  deer  PrP  have 
been  described  previously  (4).  To  generate  Tg(CerPrP-
E226) mice expressing the elk PrP coding sequence, codon 
226 of the deer PrP gene (PRNP) (GenBank accession no. 
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AF009180) was mutated from Q to E by site-directed mu-
tagenesis (Quick Change; Stratagene, La Jolla, CA, USA). 
The resulting expression cassette, CerPrP-E226, highlights 
the single amino acid difference between deer and elk PrP 
at this position (5). The coding sequence was inserted into 
the MoPrP.Xho expression vector, and the purified trans-
gene was microinjected into pronuclei of fertilized FVB/
Prnp0/0  oocytes.  Transgenic  founders  were  identified  by 
PCR screening of genomic DNA. Three Tg(CerPrP-E226) 
founders (Tg5029, Tg5034, Tg5037) were mated to FVB/
Prnp0/0 mice to produce hemizygous transgenic lines. Be-
cause  of  equivalent  levels  of  CerPrP-E226  expression, 
studies were not duplicated in the Tg5034+/– and Tg5037+/– 
lines. Estimates of the levels of PrP expression in 3 dif-
ferent Tg5037+/– mice and 5 different Tg5029+/– mice were 
accomplished by immuno-dot blotting and Western blot-
ting  using  monoclonal  antibody  (MAb)  6H4  (Prionics, 
Schlieren, Switzerland).
Preparation of Prion Inocula
Antler velvet and matching brain samples were ob-
tained from 4 elk from Canada that were naturally affected 
with CWD. Elk 01-0306 had severe CWD-specific neuro-
pathologic changes in the obex and neurologic signs indic-
ative of CWD; elk 02-0306 had moderate neuropathologic 
changes in the obex and was clinically normal. Although 
information about the clinical status of elk 03-0306 and 
04-0306 was not available, these elk had mild and severe 
neuropathologic changes, respectively, in the obex. Brain 
samples were also obtained from CWD-affected mule deer 
D10 and D92 at the Colorado Division of Wildlife, Wild-
life Research Center, and from CWD-affected elk 7378 and 
99W12389 at the Wyoming Game and Fish Department’s 
Sybille Wildlife Research Unit. Homogenates of brain and 
antler velvet (10% wt/vol) were prepared in sterile phos-
phate-buffered saline (PBS) lacking Ca2+ and Mg2+ ions.
Measurement of Incubation Times
Groups of 5-week-old Tg mice were given general an-
esthesia and inoculated with 30 µL of brain or antler velvet 
homogenate through a 27-gauge needle inserted into the 
right parietal lobe of the brain. Mice were observed 3 times 
a week for clinical signs indicative of prion infection, e.g., 
ataxia, weight loss, hyperactivity, flattened posture, absent 
extensor reflex, or kyphosis. The incubation period is the 
time between inoculation and the first day on which subse-
quently progressive clinical signs were identified. For end-
point titration, groups of 8 Tg mice were inoculated with 
10–1 to 10–10 dilutions of a 10% brain homogenate of D92 
prepared in PBS lacking Ca2+ and Mg2+ ions.
Western Blotting
Protein content in 10% brain homogenates was deter-
mined by bicinchoninic acid assay. Total protein (50 μg) 
was then digested with 40 μg/mL proteinase K (PK) (Roche, 
Mannheim, Germany) in the presence of 2% sarkosyl for 1 
h at 37°C. Digestion was terminated with phenylmethyl-
sulfonyl fluoride at a final concentration of 5 μM. Proteins 
were resolved by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis and transferred to polyvinylidene dif-
luoride  Immobilon-FL  membranes  (Millipore,  Billerica, 
MA, USA), which were immunoprobed with MAb 6H4 
followed by horseradish peroxidase–conjugated antimouse 
secondary  antibody.  Proteins  were  visualized  by  using 
ECL Plus (GE Healthcare, Piscataway, NJ, USA) and an 
FLA-5000  scanner  (Fujifilm  Life  Science,  Woodbridge, 
CT, USA).
Histoblotting
Coronal cryostat sections (10 μm) were transferred to 
nitrocellulose and probed with MAb 6H4 after PK diges-
tion as described previously (6). Images were photographed 
with a NikonDMX 1200F  (Tokyo, Japan) digital camera in 
conjunction with Metamorph software (Molecular Devices, 
Sunnyvale, CA, USA).
Immunohistochemical Analysis
Sections (8 μm) of formalin-fixed, paraffin-embedded 
mouse brains on positively charged microscope slides were 
deparaffinized  and  subjected  to  immunohistochemical 
analysis to deter the disease-associated form of PrP (PrPSc) 
as described previously (7). PrPSc was detected with MAb 
6H4 after hydrolytic autoclaving for 15 min in 10 mmol/L 
HCl. Biotinylated secondary antibody in conjunction with 
3,3′-diaminobenzidine was used to visualize PrPSc.
PMCA
Healthy Tg(CerPrP)1536+/– mice were perfused with 
PBS/5 mM EDTA. Brain homogenates (10% wt/vol) were 
prepared in conversion buffer consisting of PBS contain-
ing 150 mmol/L NaCl, 1.0% Triton X-100, and Roche’s 
Complete Protease Inhibitor Cocktail. Samples were clari-
fied by centrifugation at 500 rpm for 60 s. Each PMCA 
cycle consisted of 30 min incubation at 37°C followed by 
a 20 s sonication pulse at setting 7 using a Misonix 3000 
Sonicator (Misonix, Farmingdale, NY, USA). After 96 cy-
cles, 6 μL of the 60-μL reaction was diluted into 54 μL of 
fresh Tg(CerPrP)1536+/– substrate for a subsequent round 
of PMCA. Amplification products were digested with 50 
μg/mL PK at 50°C for 75 min.
Results
CWD Prions in Elk Antler Velvet
Mean  incubation  periods  for  mice  inoculated  with 
CWD prions from elk brains were more uniform (225–
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 5, May 2009  697 RESEARCH
335 days) than were those for mice inoculated with CWD 
prions from antler velvet. Not all Tg(CerPrP)1536+/– mice 
inoculated  with  antler  velvet  developed  disease;  incu-
bation times for those that did were relatively long and 
highly  variable  (Table).  Clinical  signs  did  develop  in 
Tg(CerPrP)1536+/–  mice  challenged  with  antler  velvet 
from elk 01-0306 and 03-0306; mean incubation periods 
were ≈440 d and ≈460 d and attack rates were 75% and 
66%,  respectively.  Tg(CerPrP)1536+/–  mice  inoculated 
with  antler  velvet  from  elk  02-0306  and  04-0306  re-
mained healthy until the mice were euthanized at ≈600 d 
postinoculation.
We  also  tested  the  susceptibility  of  Tg  mice  ex-
pressing  elk  PrP.  Mean  incubation  times  after  inocula-
tion of Tg(CerPrP-E226)5037+/– mice with CWD prions 
from brains of elk 01-0306 and 04-0306 were 174 ± 7 d 
and 224 ± 6 d, respectively (Table). Of the Tg(CerPrP-
E226)5037+/– mice inoculated with antler velvet from elk 
01-0306, 29% died of prion disease in <400 d, and antler 
velvet from elk 04-0306 failed to induce disease (Table); 
this finding confirmed the antler velvet transmission results 
in Tg(CerPrP)1536+/– mice.
Tg(CerPrP-E226)5037+/– mice express PrP at ≈5-fold 
the level of PrP in the brains of wild type mice, similar to 
transgene expression levels in Tg(CerPrP)1536+/– mice; the 
level of expression in Tg(CerPrP-E226)5029+/– mice was 
approximately equal to that in wild type mice (Figure 1). 
Induction of disease by CWD prions in brain from diseased 
elk and deer was consistently and significantly more rapid 
in  Tg(CerPrP-E226)5037+/–  than  in  Tg(CerPrP)1536+/– 
mice (Table). Mean incubation times of the D92 isolate 
were  equivalent  in  Tg(CerPrP)1536+/–  and  Tg(CerPrP-
E226)5029+/– mice (Table), which have a 5-fold difference 
in transgene expression levels (Figure 1).
PrPSc Accumulation and Neuropathologic  
Changes in Diseased Tg Mice
Diagnoses for all Tg(CerPrP)1536+/– and Tg(CerPrP-
E226)5037+/– mice were confirmed by the presence or ab-
sence  of  protease-resistant  PrPSc  in  brains,  according  to 
Western blotting (Figure 2) and histoblotting (Figure 3) 
and  finding  of  disease-specific  neuropathologic  changes 
(Figure 4). PrPSc immunostaining in histoblots of diseased 
Tg(CerPrP)1536+/–  and  Tg(CerPrP-E226)5037+/–  mice 
was punctate (Figure 3). Although cortical florid plaques 
were observed in the brains of diseased Tg(CerPrP)1536+/– 
mice (Figure 4, panels A and B), PrPSc accumulation in 
Tg(CerPrP-E226)5037+/– mice was more diffuse and granu-
lar. The extensive loss of cerebellar granular cells and ac-
companying PrPSc deposition that characterized disease in 
Tg(CerPrP-E226)5037+/– mice (Figure 4, panels G and H) 
was not noted for Tg(CerPrP)1536+/– mice (Figure 4, panels 
C and D).
Estimates of CWD Prion Titers in Antler Velvet
A  brainstem  preparation  from  CWD-affected  mule 
deer D92, which contained high levels of PrPSc according 
to Western blot (data not shown), was selected for end-
point titration of CWD prions in Tg(CerPrP)1536+/– mice. 
Disease developed in all mice inoculated with the 3 lowest 
dilutions; mean incubation periods ranged from 268 to 390 
d (Figure 5). Disease did not develop in any of the mice 
inoculated with the 10–4 dilution, but disease did develop 
after 471 d in 1 mouse from the 10–5 dilution group. The 
remaining mice in the 10–5 dilution group and all mice in-
oculated with higher dilutions remained free of disease and 
were euthanized after 560–645 d. The disease status of all 
mice was confirmed by Western blotting (data not shown). 
We estimated the titer of CWD prions in D92 brain tissue 
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Table. Transmission of chronic wasting disease prions to transgenic mice* 
Mice expressing deer PrP
C Mice expressing elk PrP
C
Tg(CerPrP)1536
+/– Tg(CerPrP-E226)5037
+/– Tg(CerPrP-E226)5029
+/–
Isolate from 
animal no.  Antler velvet  Brain Antler velvet Brain Brain % Decrease† 
01-0306 442 ± 16 (6/8)  322 ± 9 (8/8)  305 ± 86 (2/7)‡  174 ± 7 (8/8)  46 (<0.0001) 
02-0306 >594 (0/5)  225 ± 3 (7/7) 
03-0306 463 ± 23 (2/3)§  335 ± 5 (7/7) 
04-0306 >601 (0/6)  281 ± 5 (7/7)  >505 (0/5)  224 ± 6 (7/7)  20 (<0.0001) 
7378 235 ± 2 (8/8)  177 ± 15 (7/7)  25 (0.0061) 
99W12389 230 ± 9 (8/8)  158 ± 13 (7/7)  31 (0.0004) 
D10 225 ± 1 (8/8)  201 ± 8 (8/8)  11 (0.013) 
D92 268 ± 15 (7/7)  201 ± 15 (8/8)  263 ± 10 (7/7)  25 (0.0061) 
PBS >510 (0/6)
None >592 (0/4)¶ 
*Incubation times are given as mean ± SEM days. Values in parentheses are no. diseased mice/no. inoculated mice. PrP
C, cellular prion protein; Tg, 
transgenic; PBS, phosphate-buffered saline.  
†Values represent the percent decrease in mean incubation time of isolates in Tg(CerPrP-E226)5037
+/– mice compared with Tg(CerPrP)1536
+/– mice.  
p values, calculated by the Student t-test, are shown in parentheses. 
‡The remaining 5 of 7 inoculated mice remained free of disease until 525 d postinoculation, at which time they were euthanized.
§Mice inoculated with the antler velvet preparation from elk 03-0306 had an unusually high rate of intercurrent illnesses, resulting in early euthanasia of 5 
inoculated mice. 
¶Four uninoculated Tg(CerPrP E2226) 5037
+/– mice were euthanized at 437 d. CWD Prions in Elk Antler Velvet
to be 6 log i.c. ID50/g (i.c. ID50 refers to the dose of CWD 
prions that produces infection in 50% of the intracerebrally 
inoculated Tg mice) (8).
The inefficient transmission of prions from antler vel-
vet samples (Table) is consistent with low levels of CWD 
prions. Because the incubation times of CWD prions in 
antler velvet from elk 01-0306 and 03-0306 were outside 
the linear range of dose and incubation time (Figure 5), we 
were unable to assign a definitive titer. The infection attack 
rates <100% suggested that CWD prion titers in these 1% 
inocula were close to, or at, the end point of the bioassay 
(<3.5 log i.c.ID50 units).
Amplification of PrPSc in Antler Velvet Preparations
When Western blot, ELISA, and immunohistochemi-
cal analyses failed to detect PrPSc in antler velvet samples 
from 14 CWD-affected elk, including the 4 samples ana-
lyzed by bioassay (data not shown), we attempted to am-
plify PrPSc in antler velvet samples by using serial PMCA 
(Figure  6).  Whereas  PrPSc  in  brain  homogenates  of  elk 
01-0306, 03-0306, and 04-0306 was efficiently amplified, 
even at high dilution, after 1 or 2 rounds of PMCA, PrPSc 
in antler velvet homogenates of elk 01-0306 and 03-0306 
was not amplified until either round 3 or 4. PrPSc was not 
amplified in antler velvet from elk 04-0306 or after PMCA 
of negative-control preparations. PrPSc amplification cor-
related with the transmission efficiency of CWD prions in 
antler velvet. The antler velvet sample from elk 01-0306, 
which  produced  detectable  amplification  products  after 
3 rounds of PMCA, caused disease in Tg(CerPrP)1536+/– 
mice (mean incubation time 442 d, attack rate 75%) and in 
Tg(CerPrP-E226)5037+/– mice. The velvet sample from elk 
03-0306, which produced detectable amplification products 
after 4 rounds of PMCA, and resulted in a 463-d mean in-
cubation time and a 66% attack rate. In contrast, the antler 
velvet sample from elk 04-0306, which failed to amplify 
after 4 rounds of PMCA, also failed to transmit prions to 
either Tg mouse line.
Discussion
The transmission of CWD prions in antler velvet from 
2 naturally affected elk to mice in 2 Tg models demon-
strates that this tissue contains low, but detectable, amounts 
of CWD prions. In addition, serial PMCA amplified other-
wise undetectable levels of PrPSc in antler velvet.
We characterized CWD prion infectivity by end-point 
titration. The ≈6 log i.c.ID50/g CWD prion titer estimated 
by this method contrasts with ≈9 log i.c.ID50/g titers of 
mouse-adapted  scrapie  prions  in  rodent  brains  (9)  and 
≈7–7.7  log  i.c.ID50/g  titers  of  BSE  prions  estimated  by 
bioassay in transgenic mice (10,11). The linear relation-
ship between dose and incubation time (12) provides an 
opportunity to estimate the level of prions in materials con-
taining an unknown amount of infectivity. The attack rates 
of <100% after inoculation with antler velvet preparations 
from elk 01-0306 and 03-0306 and the failure to transmit 
disease from the remaining antler velvet samples suggest 
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Figure 1. Levels of transgene expression in transgenic (Tg) mice 
expressing deer or elk cellular prion protein (PrPC). Representative 
Western blot analysis of PrPC expression from different total protein 
loads in brain extracts from Tg mice Tg(CerPrP)1536+/–, Tg(CerPrP-
E226)5029+/–,  and  Tg(CerPrP-E226)5037+/–  compared  with  wild 
type and Prnp0/0 mice (knock-out mice for PrP gene).
01-0306 01-0306 03-0306 03-0306 Inoculum
PK ʵ
A A A A B B B B
PBS PBS None
B A
01-0306
Tg(CerPrP)1536+/ʵ Tg(CerPrP-E226)5037+/ʵ
+ ʵ +
Figure  2.  Accumulation  of  PrPSc 
(disease-associated form of prion 
protein)  in  diseased  transgenic 
(Tg) mice. Tg(CerPrP)1536+/– and 
Tg(CerPrPE226)5037+/–  mice  ino-
culated  with  phosphate-buffered 
saline  (PBS),  elk  brain  (B),  or 
antler  velvet  (A)  were  treated 
with  or  without  proteinase  K 
(PK).  Membranes  were  probed 
with  monoclonal  antibody  6H4. 
Molecular  weights  indicated  are 
37, 29, and 20 kD.RESEARCH
that CWD prion titers are close to, or at, the end point of 
the Tg(CerPrP)1536+/– bioassay. Although we are aware 
of the limitations of comparing levels of prions in tissues 
from different CWD-affected cervids, we estimated the end 
point of the CWD prion titration using D92 to be <3.5 log 
i.c.ID50 units. Other factors could also influence levels of 
infectivity in the 4 tested samples, e.g., the portion of the 
antler processed and the age of the antler when harvested. 
Histologic evaluation indicated that the velvet samples used 
in these transmission studies came from elk antlers in the 
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Tg(CerPrP)1536+/ʵ Tg(CerPrP-E226)5037+/ʵ
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Figure 3. Distribution of PrPSc (disease-associated form of prion protein) in brains of diseased mice. Histoblots of mice inoculated with 01-
0306 brain or antler velvet material were treated with proteinase K and probed with monoclonal antibody 6H4. Tg, transgenic.
Tg(CerPrP)1536+/ʵ
01-0306 Brain 01-0306 Antler
Tg(CerPrP-E226)5037+/ʵ
01-0306 Brain 01-0306 Antler
A B
C D
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Recipient
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Figure 4. PrPSc (disease-associated form of prion protein)–specific immunohistochemistry in the brains of diseased mice. Transgenic (Tg) 
mice Tg(CerPrP)1536+/– inoculated with brain (A) and antler velvet (B) preparations from elk 01-0306 exhibit florid PrPSc-reactive plaques 
in the cerebral cortex at the level of the thalamus but retain integrity of cerebellar granular cells (C and D). Tg(CerPrP-E226)5037+/– mice 
inoculated with brain (E) and antler velvet (F) preparations from elk 01-0306 display small plaques and diffuse granular staining in the 
cerebral cortex, PrPSc deposition, and marked cerebellar neuronal loss (G and H).CWD Prions in Elk Antler Velvet
early stages of seasonal growth (data not shown). Whether 
CWD prion titers in antler velvet vary according to the state 
of antler growth remains to be determined. Whether prion 
infectivity is derived from nervous system tissue, blood 
(13), or another component of velvet, is also unclear.
Implications for Horizontal CWD Transmission and Hu-
man Exposure 
Our studies indicate that antler velvet represents a pre-
viously unrecognized source of CWD prions in the environ-
ment. Whereas oral transmission of rodent-adapted scrapie 
prions is known to be ≈5 orders of magnitude less efficient 
than transmission by intracerebral inoculation (14,15), the 
relative efficiency of oral CWD prion transmission is un-
known. Multiple exposures to low levels of CWD prions 
in the environment (16,17), as well as increased infectivity 
when prions are bound to soil minerals (18), are factors that 
may influence transmission.
The appearance of variant Creutzfeldt-Jakob disease 
in humans exposed to bovine spongiform encephalopathy 
(BSE) (19,20) and the demonstration of CWD prions in 
muscle (3) placed the human species barrier to CWD prions 
at the forefront of public health concerns. Our studies indi-
cate that antler velvet represents an additional source for 
human exposure to CWD prions. Widely used in traditional 
Asian medicine to treat a variety of ailments including im-
potence, arthritis, and high blood pressure, antler velvet 
can be readily purchased in caplet form and its usage has 
increased worldwide.
Fortunately, to date there is no epidemiologic evidence 
that rates of CJD in the CWD-endemic region (Colorado, 
USA) have increased (21,22). Also reassuring is the ineffi-
cient in vitro conversion of human PrP to protease-resistant 
PrP by CWD (23). Two studies have shown that CWD pri-
ons failed to induce disease in Tg mice expressing human 
PrP (24,25). However, the failure of BSE to be transmit-
ted to Tg mice expressing human prion protein (HuPrP) 
was cited as early evidence of a BSE transmission barrier 
in humans (26); subsequent studies demonstrated a strong 
effect of the codon 129 polymorphism on transmissibility 
of BSE prions (27). To date, only mice expressing HuPrP 
with methionine at 129 have been challenged with CWD. 
In support of the argument that humans might be suscepti-
ble to CWD, intracerebral inoculation of squirrel monkeys 
produced disease after >30 months (28). Prion strain prop-
erties are also critical when considering the potential for 
interspecies transmission. The existence of multiple CWD 
strains has been suggested by several studies (4,25,29,30), 
but strain isolation and host range characterization have not 
been reported. Finally, it is worth considering that if CWD 
were to cross the species barrier into humans, this transmis-
sion source might not be recognized if the disease profile 
overlapped with one of the forms of sporadic CJD reported 
in North America.
Possible Role for Residue 226 in CWD Pathogenesis
Previous studies that demonstrated more rapid CWD 
prion incubation times in Tg mice expressing elk PrP (24,29) 
than in Tg(CerPrP)1536+/– mice (4) raised the possibility that 
the single amino acid difference at residue 226 between elk 
and deer PrP (5) may influence CWD pathogenesis (29). 
However,  when  the  transmission  characteristics  of  CWD 
isolates were directly compared in Tg mice expressing dif-
fering levels of deer or elk PrP, Tamgüney et al. concluded 
that CWD incubation times were related solely to the level 
of PrP transgene expression (25). We compared CWD trans-
mission in Tg(CerPrP-E226)5037+/– and Tg(CerPrP)1536+/– 
mice, which express PrP at levels ≈5-fold higher than PrP 
levels in wild type mouse brain (Figure 1A), and found that 
CWD transmission was consistently and substantially more 
rapid in Tg(CerPrP-E226)5037+/– mice. Our results appear 
compatible with more efficient CWD prion propagation by 
elk cellular prion protein (CerPrPC) containing E at residue 
226 than by deer CerPrPC containing Q at this position. Con-
sistent with this interpretation, despite 5-fold lower levels of 
transgene expression in Tg(CerPrP-E226)5029+/– mice than 
in Tg(CerPrP)1536+/– mice, mean incubation times of the 
D92 isolate were equivalent in these 2 lines (Table). None-
theless, undetected differences in CerPrPC expression, for 
example in particular cell types, might result in more rapid 
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Figure 5. Quantification of chronic wasting disease prions. Diseased 
transgenic (Tg) mice Tg(CerPrP)1536+/– inoculated with dilutions of 
brain homogenate are indicated by filled symbols Asymptomatic 
mice are indicated by open circles; time at which asymptomatic 
aged mice were either euthanized or died of illnesses unrelated to 
prion disease is shown. Error bars indicate SEM. n/n0 refers to the 
number of mice developing prion disease divided by the number 
of inoculated mice. Also shown are the mean incubation times of 
diseased  Tg(CerPrP)1536+/–  mice  inoculated  with  antler  velvet 
preparations (filled squares).RESEARCH
disease and/or altered pathologic changes. The generation of 
transgenic mice expressing elk and deer coding sequences 
using gene replacement strategies would seem to be an ex-
cellent approach for resolving this issue.
The different responses to CWD in Tg mice also appear 
to recapitulate aspects of CWD pathogenesis in the natu-
ral hosts. Previous limited comparative transmission stud-
ies indicated that CWD developed ≈25% more rapidly in 
orally challenged elk than deer (31). Although plaques were 
not detected in brains of CWD-affected elk, florid plaques 
have been observed in the brains of diseased deer (32,33). 
Similar differences in pathologic changes were observed in 
Tg(CerPrP-E226)5037+/– and Tg(CerPrP)1536+/– mice (Fig-
ure 4). Structural analyses suggest that residue 226 is located 
within a region of PrPC proposed to interact with a factor 
(34), possibly equivalent to the postulated protein X (35). 
Although mutation of the equivalent residue from Q to lysine 
(K) in epitope-tagged mouse PrP had no effect on PrPSc for-
mation in transfected chronically infected ScN2A cells, the 
effects of the Q-to-E substitution were not assessed (36).
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